S&P 500   3,122.63 (+0.02%)
DOW   27,948.65 (-0.31%)
QQQ   203.47 (+0.20%)
CGC   15.27 (+7.38%)
BABA   184.30 (-0.17%)
GE   11.51 (+0.61%)
T   38.11 (-3.84%)
F   8.89 (-0.67%)
BAC   32.96 (+0.00%)
S&P 500   3,122.63 (+0.02%)
DOW   27,948.65 (-0.31%)
QQQ   203.47 (+0.20%)
CGC   15.27 (+7.38%)
BABA   184.30 (-0.17%)
GE   11.51 (+0.61%)
T   38.11 (-3.84%)
F   8.89 (-0.67%)
BAC   32.96 (+0.00%)
S&P 500   3,122.63 (+0.02%)
DOW   27,948.65 (-0.31%)
QQQ   203.47 (+0.20%)
CGC   15.27 (+7.38%)
BABA   184.30 (-0.17%)
GE   11.51 (+0.61%)
T   38.11 (-3.84%)
F   8.89 (-0.67%)
BAC   32.96 (+0.00%)
S&P 500   3,122.63 (+0.02%)
DOW   27,948.65 (-0.31%)
QQQ   203.47 (+0.20%)
CGC   15.27 (+7.38%)
BABA   184.30 (-0.17%)
GE   11.51 (+0.61%)
T   38.11 (-3.84%)
F   8.89 (-0.67%)
BAC   32.96 (+0.00%)
Log in

Global Blood Therapeutics Stock Price, Forecast & Analysis (NASDAQ:GBT)

$55.04
+3.14 (+6.05 %)
(As of 11/19/2019 03:49 PM ET)
Today's Range
$51.44
Now: $55.04
$55.20
50-Day Range
$46.02
MA: $48.60
$51.39
52-Week Range
$30.15
Now: $55.04
$64.94
Volume87,604 shs
Average Volume674,164 shs
Market Capitalization$3.32 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.57
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GBT
CUSIPN/A
Phone650-741-7700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$10.97 per share

Profitability

Net Income$-174,190,000.00

Miscellaneous

Employees171
Market Cap$3.32 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive GBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter.


Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics Inc (NASDAQ:GBT) posted its earnings results on Thursday, November, 7th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($1.03) by $0.04. During the same period in the previous year, the firm posted ($0.83) earnings per share. View Global Blood Therapeutics' Earnings History.

When is Global Blood Therapeutics' next earnings date?

Global Blood Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Global Blood Therapeutics.

What price target have analysts set for GBT?

13 brokerages have issued 1 year price targets for Global Blood Therapeutics' shares. Their forecasts range from $50.00 to $150.00. On average, they anticipate Global Blood Therapeutics' share price to reach $90.92 in the next twelve months. This suggests a possible upside of 65.5% from the stock's current price. View Analyst Price Targets for Global Blood Therapeutics.

What is the consensus analysts' recommendation for Global Blood Therapeutics?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Global Blood Therapeutics.

What are Wall Street analysts saying about Global Blood Therapeutics stock?

Here are some recent quotes from research analysts about Global Blood Therapeutics stock:
  • 1. HC Wainwright analysts commented, "Our Buy rating and $150 PT are based on a DCF analysis, derived using a beta of 1.58, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.8%, and tax rate of 15% beginning in FY 2024. We estimate approximately 70K patients in U.S., 42K patients in the $60K U.S. and EU launch prices, respectively, a 2020 commercial launch, 70% compliance, and 23% gross-to-net. In 2022, we model global sales at roughly $820M and expect voxelotor peak sales of $2.7B during 2026, which assumes about 49% adoption across the developed nations, and a POS of 75%." (8/8/2019)
  • 2. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (3/4/2019)
  • 3. William Blair analysts commented, "We continue to view the stock as substantially de-risked with the completion of 24 weeks of therapy in the additional 118 enrolled patients in the Phase III HOPE study , publication of the HOPE Part A data set, and a pre-NDA meeting update in the first half as well as potential Subpart H filing in the second half as key catalysts for shares this year . We also see the company as a potential takeout candidate given the significant unmet medical need in sickle cell disease, the impressive data shown in patients with or without concomitant hydroxyurea, and the alignment of a once-daily , oral therapy dosed (potentially) in perpetuity with the large pharma commercial model. GBT remains our top pick for 2019." (1/30/2019)

Has Global Blood Therapeutics been receiving favorable news coverage?

News headlines about GBT stock have been trending somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Global Blood Therapeutics earned a daily sentiment score of 1.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Global Blood Therapeutics.

Who are some of Global Blood Therapeutics' key competitors?

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Cynosure (CYNO), Alibaba Group (BABA), Exelixis (EXEL), TherapeuticsMD (TXMD), AbbVie (ABBV), Adobe (ADBE), Sarepta Therapeutics (SRPT) and Vertex Pharmaceuticals (VRTX).

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the folowing people:
  • Dr. Ted W. Love, Pres, CEO & Director (Age 60)
  • Dr. Charles J. Homcy, Founder, Advisor & Director (Age 71)
  • Mr. Jeffrey S. Farrow, Chief Financial Officer (Age 57)
  • Mr. Peter Radovich, Sr. VP of Operations (Age 41)
  • Dr. Hing Sham, Sr. VP of Research (Age 67)

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an IPO on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Who are Global Blood Therapeutics' major shareholders?

Global Blood Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Eagle Asset Management Inc. (0.74%), Rice Hall James & Associates LLC (0.39%), GW&K Investment Management LLC (0.24%), Alps Advisors Inc. (0.20%), California Public Employees Retirement System (0.19%) and Rhumbline Advisers (0.13%). Company insiders that own Global Blood Therapeutics stock include De Dominicis Robert, Deval L Patrick, Joshua Lehrer-Graiwer, Jung Choi, Lesley Ann Calhoun, Perceptive Advisors Llc, Peter Radovich and Tricia Borga Suvari. View Institutional Ownership Trends for Global Blood Therapeutics.

Which major investors are selling Global Blood Therapeutics stock?

GBT stock was sold by a variety of institutional investors in the last quarter, including Bailard Inc., First Midwest Bank Trust Division, Oppenheimer & Co. Inc., Tower Research Capital LLC TRC , Dupont Capital Management Corp and Janney Montgomery Scott LLC. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Deval L Patrick, Joshua Lehrer-Graiwer, Lesley Ann Calhoun and Tricia Borga Suvari. View Insider Buying and Selling for Global Blood Therapeutics.

Which major investors are buying Global Blood Therapeutics stock?

GBT stock was purchased by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, California Public Employees Retirement System, State of New Jersey Common Pension Fund D, GW&K Investment Management LLC, Profit Investment Management LLC, Eagle Asset Management Inc., SG Americas Securities LLC and Nisa Investment Advisors LLC. View Insider Buying and Selling for Global Blood Therapeutics.

How do I buy shares of Global Blood Therapeutics?

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $54.94.

How big of a company is Global Blood Therapeutics?

Global Blood Therapeutics has a market capitalization of $3.31 billion. The company earns $-174,190,000.00 in net income (profit) each year or ($3.41) on an earnings per share basis. Global Blood Therapeutics employs 171 workers across the globe.View Additional Information About Global Blood Therapeutics.

What is Global Blood Therapeutics' official website?

The official website for Global Blood Therapeutics is http://www.gbt.com/.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]


MarketBeat Community Rating for Global Blood Therapeutics (NASDAQ GBT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  470 (Vote Outperform)
Underperform Votes:  295 (Vote Underperform)
Total Votes:  765
MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe GBT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GBT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel